Equity Overview
Price & Market Data
Price: $3.65
Daily Change: -$0.10 / 2.74%
Range: $3.64 - $3.90
Market Cap: $2,687,973
Volume: 19,300
Performance Metrics
1 Week: -6.89%
1 Month: 1.65%
3 Months: 21.26%
6 Months: -23.06%
1 Year: -69.33%
YTD: -13.30%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.